Inari Medical (NARI)
(Delayed Data from NSDQ)
$57.98 USD
+3.18 (5.80%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $58.68 +0.70 (1.21%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Price, Consensus and EPS Surprise
NARI 57.98 +3.18(5.80%)
Will NARI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NARI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NARI
Here's Why You Should Retain Inari Medical (NARI) for Now
Veracyte (VCYT) Up 8.4% Since Last Earnings Report: Can It Continue?
NARI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inari's (NARI) Expanding Product Portfolio Offsets Competition
Inari Medical (NARI) Sues Truvic on Patent Infringement
Here's Why You Should Retain Inari Medical (NARI) for Now
Other News for NARI
Inari Medical to Announce Second Quarter 2024 Financial Results
Insider Sale: Chief Medical Officer Thomas Tu Sells Shares of Inari Medical Inc (NARI)
Inari Medical's ThomasTu sells over $910K in company shares
Inari Medical price target raised by $13 at Truist, here's why
Class Action Lawsuit Against Inari Medical, Inc. (NASDAQ:NARI)